List view / Grid view
28 March 2017 | By Robert Groebel, Vice President of global medical strategy, Veeva
Veeva's Robert Groebel lays out the best practices toward a more coordinated, better healthcare stakeholder experience...
22 March 2017 | By Russ Pimblett, Business Development Manager (Food, Pharmaceutical and Biomedical), FTL
FTL's Russ Pimblett talks us through sealing issues: colour options, materials choices, hygiene concerns and how to be cost effective and safe...
21 March 2017 | By Kaspar van den Dries PhD, Senior Director and Principal Scientist, Solid Dose Development, Patheon
Patheon's Kaspar van den Dries shows the advantages of considering lipid formulation in early development to optimise a molecule’s developability...
15 March 2017 | By Mike Elliott, Vice President, Medical Affairs, Gilead Sciences
We caught up with Gilead’s Mike Elliott to find out the latest in HIV medication and whether a cure is finally within our reach…
8 March 2017 | By Mark Davison, CEO, Blue Sphere Health Ltd
Blue Sphere Health’s CEO, Mark Davison, outlines how to achieve positive return on investment (ROI) from a cost-effective serialisation initiative…
6 March 2017 | By Niamh Marriott, Junior Editor
We’re live at PITTCON 2017! Check this stream for live updates of the event…
1 March 2017 | By Dorothea Wenzel, Senior VP Global Business Franchise Fertility, Merck
We caught up with Merck's Dorothea Wenzel to hear all about the latest in fertility treatments, training and technologies and to find out the truth about infertility...
1 March 2017 | By Niamh Louise Marriott, Digital Editor
This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).
A defining characteristic of inhaled drug delivery is variability in the dose received by the patient, as a result of physiology, for example, or the technique applied during use. This variability directly affects clinical outcomes so reducing it to a minimum is an important goal for the industry...
For the pharmaceutical scientist, the journey of an active molecule from the end of its synthetic pathway and crystallisation to its ultimate site of action is a fascinating one, and one that is necessary to understand...
Commercial biomanufacturing dates to thousands of years and the first biological engine, the yeast, continues to be beneficial...
Near-infrared spectroscopy (NIRS) is used by the pharmaceutical industry for a wide variety of applications, including the identification of drug substances, products and raw materials; tablet assays; uniformity of content; water content; solid state form; and process analytical technologies...
Near-infrared spectroscopy (NIRS) is a rapid and non-destructive analytical technique that is important in analysing or profiling both solid and liquid dosage forms, as well as biotechnological products...
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
Pharmaceutical QbD: Omnipresence in the product development lifecycle; Expert View with Kaiser Optical Systems Inc.; and Reinventing commercial biomanufacturing...
